OR WAIT null SECS
In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.
Few names are carried in the same esteem within the diabetes community as Richard Bergenstal, MD. The former president of Science and Medicine with the American Diabetes Association, Bergenstal served as the principal investigator for multiple landmark trials that have contributed to current standards of care in both type 1 and type 2 diabetes, including the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes, the Action to Control Cardiovascular Risks in Diabetes (ACCORD) study, and the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study.
Currently serving as an endocrinologist and Executive Director of the International Diabetes Center, Bergenstal has been a champion of advancing diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, since the advent of these technologies. During his time at the Association of Diabetes Care and Education Specialists Diabetes Technology Conference 2022 in Chicago, Bergenstal sat down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special edition episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives.
In the episode, Bergenstal discusses the role and evolution of continuous glucose monitoring and automated insulin delivery systems, as well as other technologies, in the management of diabetes. Later, Bergenstal offers perspective on ongoing research and future needs as the field looks to optimize the application of these technologies.